Form 8-K - Current report:
SEC Accession No. 0000950170-25-041187
Filing Date
2025-03-18
Accepted
2025-03-18 16:10:54
Documents
13
Period of Report
2025-03-18
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-20250318.htm   iXBRL 8-K 54221
2 EX-99.1 trvi-ex99_1.htm EX-99.1 145174
3 GRAPHIC img251553556_0.jpg GRAPHIC 29443
  Complete submission text file 0000950170-25-041187.txt   370085

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20250318.xsd EX-101.SCH 28532
15 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20250318_htm.xml XML 4711
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 25748390
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)